Insofar as it exerted its immunosuppressive effect by inhibiting cytokine expression, we assessed the effect of FK506 (Tacrolimus) on cytokine-stimulated T-cell activation. Human T cells, treated with FK506, or controls were stimulated with the mitogens PHA + PMA, Con A, and the "CD3-bypass" stimulation regimen, PMA + ionomycin. T-cell proliferation was quantitated by measuring the uptake of tritiated thymidine, and mRNA expression was assessed by RT-PCR. FK506, in a concentration-dependent fashion, inhibited T-cell proliferation and steady-state mRNA expression of IL-2 and IL-7; half-maximal suppression was obtained at 10 −7 to 5 × 10 −8 M. We tested whether FK506 antiproliferative effect could be overcome with exogenously reconstituted rIL-2 and/or rIL-7. Neither rIL-2 nor rIL-7, individually in conjunction with suboptimal concentrations of PHA or Con A, or in combination without any costimulus, was capable of abrogating FK506 antiproliferative effect, indicating that FK506 also acted by inhibiting cytokine-stimulated T-cell activation. To confirm this, T cells were treated with FK506 and stimulated by rIL-2 and rIL-7, individually in conjunction with suboptimal concentration of PHA and Con A. In addition, T cells were stimulated with rIL-2 and rIL-7 without any costimuli. FK506 inhibited T-cell activation stimulated by rIL-2 and by rIL-7, individually and in combination. This confirms that, in exerting its antiproliferative effect, FK506 acts at two levels, by inhibiting cytokine availability and by suppressing cytokine effect on target cells, and explains the beneficial effect of FK506 in attenuating ongoing immune responses.
INTRODUCTION
suppressive activity, and is used in combating disorders of heightened immunity, including organ transplantation (19,25) and allergic disorders (35, 36) , owing to its ca-T-cell activation by antigens, mitogens, or receptor cross-linking antibodies (as surrogates of antigenic stimpacity to inhibit the expression of multiple T-cell-derived cytokines. Mechanistically, FK506 exerts its effect ulation) results from ligation of the T-cell receptor (TcR)-CD3 complex with antigenic fragments coexby forming a complex with its cytoplasmic receptor, FK506 binding protein (FKBP) (7,26), which subsepressed with MHC class II molecules by antigen-presenting cells (9). The provision of cell-bound and sequently binds to and antagonizes the activity of calcineurin (12, 14) . This results in inhibition of the activation creted costimulatory molecules, while not imparting antigenic specificity, greatly augments T-cell activation and nuclear translocation of nuclear factor of activated (17, 20) , resulting in the activation of at least three major T cells (NF-AT), and hence IL-2 gene transcription signal transduction pathways (3) . These converge at in- (24, 47) . Similarly, CsA binds to its cytosolic receptor, duction of cytokine gene expression, and stimulation of cyclophilin (18, 26, 32) , and the CsA-cyclophilin comcellular activation. Interruption of any of the events of plex then antagonizes calcineurin activity (6, 12, 33) . Col-T-cell activation by the immunosuppressants cyclosporin lectively, this suggested that the calcinuerin-NF-AT A (CsA), FK506, glucocorticoids, and rapamycin (1,3, pathway is required for proper IL-2 and other cytokine 15,24) resulted in downstream inhibition of cytokine exgene transcription (12,39). Rapamycin, structurally repression and T-cell proliferation (3, 24, 41 Cetus, Branchburg, NJ), dNTP mixture (at 10 mM final pended in RPMI-1640 medium (Gibco, Burlington, Onconcentration; Pharmacia), and Taq DNA polymerase tario) supplemented with 10% human type AB serum (1.5 U, Perkin-Elmer Cetus). The oligonucleotide prim-(Whittaker, Bethesda, MD), 2 mM L-glutamine (Gibco), ers for IL-2 had the following sequence: forward 5′-penicillin-streptomycin (100 IU/ml and 100 µg/ml, re-ATG AGA AGG ATG CTT CTG\T-CAC; reverse 5′-AGG spectively; Gibco), and shall be referred to hereafter as GCT TGT TGA GAT GAT GCT. The primer sequence "complete medium." PBML were incubated at 10 7 cells/ for IL-7 was: forward 5′-ATG TTC CAT GTT TTC TTT ml in plastic petri dishes for 1 h at 37°C; nonadherent TAG G; reverse 5′-AGC TTT TAG TGC CCA TCA AAA cells were further applied on a nylon wool column pre-TTT TAT TCC AAC A. PCR conditions comprised deequilibrated with complete medium and incubated for naturation for 45 s at 92°C and annealing and extension 1 h at 37°C. This T-cell-enriched population was then for 2 min at 60°C for 34 cycles in a PTC-100 thermal subjected to anti-CD19 (Cedarlane Laboratories, Missiscycler (M. J. Research Inc., Watertown, MA). Amplified sauga, Ontario) plus complement treatment, and was reproducts were the analyzed by agarose (2%) gel electrosuspended in complete medium; T-cell purity was deterphoresis and visualized by UV transillumination. mined by FACS analysis (>98.5% CD3+) and by the failure of the T cells to proliferate in response to PHA Statistical Analysis (5 µg/ml) stimulation.
The mean ± SEM was calculated for each experiment. Analysis of variance (ANOVA) followed by StuReagents and Drugs dent-Newman-Keuls (SNK) analysis was performed to Recombinant human IL-2 (rIL-2) was a gift from Dr. assess intergroup differences. Statistical significance Steven Gillis (Immunex Corp., Seattle, WA), and rIL-7 was set at p < 0.05. was kindly provided by Dr. Connie Faltynek, Sterling Research Group (Malvern, PA). FK506 (Fujisawa Phar-RESULTS maceutical Company, Deerfield, IL) was prepared as Inhibition of T-Cell Proliferation by FK506 stock solutions of 10 mM in 95% ethanol; further diluThe antiproliferative capacity of FK506 was assessed tions were made in complete medium. Phytohemagglutiby adding FK506 to T cells stimulated with PHA (5 µg/ nin (PHA-P) was purchased from Difco Laboratories (Detroit, MI), and phorbol-12β-myristate-13α-acetate ml) + PMA (5 ng/ml), Con A (5 µg/ml), or with PMA (5 ng/ml) + ionomycin (0.1 µM). Data from Figure 1 or rIL-7, at 25-250 U/ml, to T cells treated with FK506 (1 µM) and stimulated with PHA + PMA. Neither rIL-2 show that FK506, in a concentration-dependent manner, inhibited T-cell proliferation stimulated by the three nor rIL-7, at the concentrations tested, was capable of abrogating FK506-mediated inhibition of T-cell proliferstimulation regimens, with EC 50 (concentration yielding half-maximal suppression) value calculated at 100 nM. ation (Fig. 3) . Furthermore, the combination of rIL-2 and rIL-7 (at 250 U/ml for each cytokine) also failed to Ethanol, at all concentrations tested, was devoid of any antiproliferative capacity.
abrogate FK506-mediated antiproliferative effect (data not shown).
Effect of FK506 on Cytokine Steady-State mRNA Expression
Inhibition of Cytokine-Stimulated T-Cell Proliferation by FK506 The effect of FK506 on cytokine steady-state IL-2 and IL-7 mRNA expression was assessed by RT-PCR.
In view of the failure of recombinant cytokines, indi-T cells (2 × 10 6 cells/ml) treated with FK506 at 10 −10 to vidually or in combination, to overcome FK506 antipro-10 −5 M were stimulated with PHA + PMA and cultured liferative effect, we tested the possibility that FK506 infor 16-20 h at 37°C. FK506 inhibited the steady-state hibited cytokine-stimulated T-cell proliferation, in mRNA expression of IL-2 and IL-7 stimulated by PHA addition to suppressing cytokine expression. To assess + PMA (Fig. 2) , or with Con A and PMA + ionomycin cytokine-stimulated T-cell proliferation, primary T cells (data not shown). FK506-mediated inhibition of IL-2 were stimulated with rIL-2 or rIL-7 in conjunction with and IL-7 steady-state mRNA expression was paralleled suboptimal concentrations of PHA (0.5 µg/ml) (Fig. 4A ) by inhibition of IL-2 and IL-7 secretion, determined by or Con A (0.5 µg/ml) (Fig. 4B ). T cells were also stimu-ELISA (data not shown).
lated by rIL-2 plus rIL-7 without any other costimuli (data not shown). rIL-2 and rIL-7, in the presence of Failure of Recombinant Cytokines to Abrogate suboptimal PHA or Con A concentrations, stimulated FK506 AntiProliferative Effects vigorous T-cell proliferation when combined with PHA (Fig. 4A ) or Con A (Fig. 4B) , which was maximal at We reasoned that if FK506 inhibited T-cell proliferaconcentrations of 50 U/ml or higher. Thus, standard rILtion by inhibiting IL-2 and IL-7 production, then recons-2 and rIL-7 concentrations of 100 U/ml and 150 U/ml, titution with rIL-2 and/or rIL-7 should abrogate FK506 antiproliferative effect. This was tested by adding rIL-2 respectively, were used in subsequent experiments. The effect of FK506 on rIL-2-and rIL-7-stimulated was added to T cells stimulated with rIL-2 + rIL-7 without any additional costimulus (Fig. 6) . FK506, in a con-T-cell proliferation was determined. FK506 was added to T cells stimulated with rIL-2 (100 U/ml) (Fig. 5A) or centration-dependent manner, inhibited T-cell proliferation stimulated by rIL-2 ( Fig. 5A ) and rIL-7 (Fig. 5B ), rIL-7 (150 U/ml) (Fig. 5B ) in combination with PHA (0.5 µg/ml) or Con A (0.5 µg/ml). In addition, FK506
in conjunction with submitogenic concentrations of PHA or Con A. FK506 also suppressed T-cell proliferaprincipally by antagonizing calcineurin (12,14), and hence attenuating NF-AT activation and nuclear translotion induced by rIL-2 + rIL-7 (Fig. 6) , with a calculated EC 50 of 5 × 10 −7 M. cation. However, little is known about its effect on cytokine-stimulated T-cell activation. Recent findings (2), DISCUSSION including clinical observations (13,38), suggested that It is well established that, similar to cyclosporin A FK506 and cyclosporin A antiproliferative effects are not identical, and that FK506-induced immunosuppresbut not rapamycin, FK506 inhibited cytokine production sion is not exclusively due to interruption of NF-AT without costimuli. Although rIL-2 and rIL-7 were incapable of eliciting any significant proliferative response pathway (2,38,41), but may involve, in addition, blockade of cytokine effects on target cells (35) . Our results if tested individually, as shown here and elsewhere (4, 10, 45) , the inclusion of rIL-2 or rIL-7 in PHA-and clearly favor the notion that FK506 acts at two levels, first by inhibiting cytokine production through reducing Con A-stimulated cultures provided a costimulatory signal, which stimulated cellular proliferation (37,45). In the availability of NF-AT, and second by attenuating cytokine effect on target cells. addition, the combination of rIL-2 and rIL-7 without any additional costimuli was effective in driving a vigorous The T-cell preparations used were APC depleted, verified by their inability to respond to PHA stimulation proliferative response. The alleged ability of rIL-7 to The generalizability of conclusions pertaining to costimuli (4,45) was probably due to residual contamination with accessory cells, which was evidenced by the the effects of FK506 on cytokine-driven responses must be verified by performing parallel experiments on pribrisk proliferative response of "purified" T cells to PHA (1-5 µg/ml) stimulation (45). With the exception of thymary nonimmortalized cells, as done here. This indicated that FK506 acted at two sites: proximocytes where rIL-2 and rIL-7 stimulated cellular proliferation individually (40,44), neither rIL-2 nor rIL-7 mally inhibiting IL-7 expression, and distally by inhibiting T-cell responsiveness (proliferation) to IL-7. The latstimulated proliferation of mature T cells unless provided with a costimulus (37).
ter potentially involves an earlier blockade of IL-7 receptor expression by FK506 (induction of Cp93 and Similar to its effect on IL-2 and IL-4 mRNA expression (21,23,43), FK506 inhibited IL-7 steady-state downregulation of Cp107 IL-7R forms), and hence attenuation of the response to rIL-7 stimulation, as was mRNA expression without affecting the transcription of a constitutively expressed gene (β-actin). Antiproliferasuggested (16) . However, our results were in disagreement with those of Foxwell et al. (16), who suggested tive concentrations of FK506 paralleled those required for inhibition of the expression of IL-2 and IL-7, further that rIL-7 was capable of abolishing FK506-mediated inhibition of IL-7R (Cp93) expression and IL-7-stimusupporting the notion that FK506 suppressed cellular proliferation by inhibiting cytokine gene expression lated T-cell proliferation. In our hands, we could not reproduce some of their results because neither PMA (43,47). We reasoned that if FK506 acts by inhibiting cytokine expression, then recombinant cytokines should nor ionomycin elicited any significant proliferative response if tested individually (background CPM, 204 ± abrogate FK506 antiproliferative effects. Results obtained did not support this assumption, because FK506 54; PMA-stimulated cells, 487 ± 171; ionomycin-stimulated cells, 2664 ± 429). That was in sharp contrast to inhibited cytokine (rIL-2 and rIL-7)-driven T-cell proliferation, in agreement with reports documenting the failthe vigorous T-cell proliferative response elicited in response to ionomycin and PMA stimulation (82,486 ± ure of rIL-2 to overcome FK506-mediated effects (34), but in apparent contradiction with others that showed 12,043), in accord with earlier reports pertaining to the synergistic effect of PMA + ionomycin in driving T-cell that FK506 did not affect IL-2-driven responses (15, 23, 30) . In the latter cases, FK506 effects were asproliferation (5,34). The most significant finding in this study is that sessed in cytokine-dependent cell lines. As such, this apparent discrepancy may be explained by differences FK506 inhibited both the production of and the proliferative response to IL-2 and IL-7. Accordingly, FK506 in cytokine dependency and hence cytokine-stimulated provide for an additional mechanism of FK506 antipro-
